Compare PHIN & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PHIN | NEO |
|---|---|---|
| Founded | 2023 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Precision Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.6B |
| IPO Year | N/A | 1999 |
| Metric | PHIN | NEO |
|---|---|---|
| Price | $68.52 | $12.92 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $60.80 | $11.38 |
| AVG Volume (30 Days) | 441.8K | ★ 1.8M |
| Earning Date | 02-12-2026 | 02-17-2026 |
| Dividend Yield | ★ 1.56% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.18 | N/A |
| Revenue | ★ $3,427,000,000.00 | $709,162,000.00 |
| Revenue This Year | $3.03 | $10.87 |
| Revenue Next Year | $1.40 | $9.84 |
| P/E Ratio | $31.78 | ★ N/A |
| Revenue Growth | N/A | ★ 10.10 |
| 52 Week Low | $36.25 | $4.72 |
| 52 Week High | $70.03 | $16.18 |
| Indicator | PHIN | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 75.56 | 60.93 |
| Support Level | $64.74 | $11.93 |
| Resistance Level | $70.03 | $13.74 |
| Average True Range (ATR) | 1.61 | 0.59 |
| MACD | 0.36 | 0.03 |
| Stochastic Oscillator | 83.84 | 64.30 |
Phinia Inc is engaged in the development, design, and manufacture of integrated components and systems that optimize performance, increase efficiency, and reduce emissions in combustion and hybrid propulsion for commercial vehicles, industrial applications, and light vehicles. Its product portfolio includes alternative fuel systems, fuel delivery modules, evaporative canisters, diesel fuel injection systems, electrical systems, hydrogen solutions, associated software, and others. The company's reportable segments are; the Fuel Systems segment, which derives key revenue, and the Aftermarket segment. Geographically, the company generates maximum revenue from the United States and the rest from the United Kingdom, China, Poland, Romania, Brazil, and other regions.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.